The main goals of Ulcerative Colitis (UC) treatment are to both induce and maintain the
clinical and endoscopic remission of disease, reduce the incidence of complications such as …

Background One-third of patients with acute severe ulcerative colitis [ASUC] are steroid-
refractory. We aimed to review the different options for the management of steroid-refractory …

Simple Summary Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory
bowel diseases that affect the gut and extraintestinal organs. Preliminary evidence has …

(1) Background: GP2017 is one of the biosimilar drugs of adalimumab, one of the anti-TNF
agents used for inflammatory bowel disease (IBD). To date, there is little real-world data …

Background Crohn's disease and ulcerative colitis are inflammatory bowel diseases (IBDs)
with a rapidly growing worldwide incidence. The last decades presented rapid progress in …

The drug pipeline for the treatment of inflammatory bowel disease (IBD) has dramatically
expanded over the last two decades, and it is expected to further grow in the upcoming …

Background Real-world evidence is needed to determine the value of tofacitinib (TOFA) for
the treatment of ulcerative colitis (UC). Aim To assess the safety and effectiveness of TOFA …

This study mainly investigated the regulatory effect of Rosa roxburghii Tratt fruit juice
fermented by Lacticaseibacillus paracasei SR10-1 (LAB-RRTJ) on modulating gut …

Background Many patients with inflammatory bowel disease (IBD) use complementary and
alternative medicine (CAM) for disease management. There is, however, a communication …

An increasing amount of research explores the role of race in clinical phenotypes and
outcomes in ulcerative colitis (UC). We aimed to investigate racial differences in infliximab …